Mind Medicine (MindMed) Inc. (MNMD)

Market Cap	974.69M
Revenue (ttm)	n/a
Net Income (ttm)	-114.52M
Shares Out	76.09M
EPS (ttm)	-1.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,128,016
Open	12.08
Previous Close	11.97
Day's Range	11.92 - 12.94
52-Week Range	4.70 - 12.94
Beta	3.31
Analysts	Strong Buy
Price Target	26.50 (+106.87%)
Earnings Date	Nov 6, 2025

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: MNMD
• Website: https://www.mindmed.co

Analyst Summary

According to 6 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price target is $26.5, which is an increase of 106.87% from the latest price.

Price Target

$26.5

(106.87% upside)

Analyst Consensus: Strong Buy